News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
726,272 Results
Type
Article (41143)
Company Profile (264)
Press Release (684851)
Multimedia
Podcasts (85)
Webinars (20)
Section
Business (204753)
Career Advice (2027)
Deals (35552)
Drug Delivery (121)
Drug Development (81448)
Employer Resources (173)
FDA (16466)
Job Trends (14964)
News (346616)
Policy (32748)
Tag
2027 BioCapital Elite (1)
2027 Biotech Bay Standard (2)
2027 Genetown Elite (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2584)
Accelerated approval (42)
Adcomms (25)
Allergies (160)
Alliances (49579)
ALS (192)
Alzheimer's disease (1739)
Antibody-drug conjugate (ADC) (366)
Approvals (16783)
Artificial intelligence (593)
Autoimmune disease (222)
Automation (50)
Bankruptcy (362)
Best Places to Work (11636)
BIOSECURE Act (20)
Biosimilars (201)
Biotechnology (174)
Bladder cancer (177)
Brain cancer (63)
Breast cancer (685)
Cancer (5300)
Cardiovascular disease (442)
Career advice (1716)
Career pathing (39)
CAR-T (299)
CDC (53)
Celiac Disease (2)
Cell therapy (796)
Cervical cancer (41)
Clinical research (70216)
Collaboration (1884)
Company closure (4)
Compensation (1270)
Complete response letters (69)
COVID-19 (2724)
CRISPR (98)
C-suite (973)
Cystic fibrosis (148)
Data (7038)
Decentralized trials (3)
Denatured (26)
Depression (152)
Dermatology (57)
Diabetes (549)
Diagnostics (6823)
Digital health (52)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (292)
Drug pricing (194)
Drug shortages (29)
Duchenne muscular dystrophy (265)
Earnings (91056)
Editorial (60)
Employer branding (21)
Employer resources (152)
Events (118339)
Executive appointments (1030)
FDA (19878)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (14)
Frontotemporal dementia (29)
Funding (1609)
Gene editing (210)
Generative AI (51)
Gene therapy (652)
GLP-1 (1014)
Government (4692)
Grass and pollen (6)
Guidances (396)
Healthcare (18919)
HIV (73)
Huntington's disease (52)
IgA nephropathy (91)
Immunology and inflammation (271)
Immuno-oncology (80)
Indications (157)
Infectious disease (3036)
Inflammatory bowel disease (200)
Inflation Reduction Act (14)
Influenza (128)
Intellectual property (273)
Interviews (316)
IPO (16649)
IRA (50)
Job creations (3645)
Job search strategy (1429)
JPM (58)
Kidney cancer (18)
Labor market (92)
Layoffs (553)
Leadership (34)
Legal (7952)
Liver cancer (98)
Longevity (28)
Lung cancer (712)
Lymphoma (406)
Machine learning (52)
Management (59)
Manufacturing (917)
MASH (176)
Medical device (13849)
Medtech (13926)
Mergers & acquisitions (20060)
Metabolic disorders (1406)
mRNA (173)
Multiple sclerosis (172)
NASH (17)
Neurodegenerative disease (380)
Neuropsychiatric disorders (97)
Neuroscience (3124)
Neurotech (1)
NextGen: Class of 2026 (6521)
Non-profit (4525)
Now hiring (73)
Obesity (661)
Opinion (274)
Ovarian cancer (185)
Pain (227)
Pancreatic cancer (253)
Parkinson's disease (336)
Partnered (33)
Patents (552)
Patient recruitment (587)
Peanut (60)
People (59225)
Pharmaceutical (59)
Pharmacy benefit managers (32)
Phase 1 (21887)
Phase 2 (30915)
Phase 3 (23024)
Pipeline (7093)
Policy (302)
Postmarket research (2564)
Preclinical (9277)
Press Release (64)
Prostate cancer (274)
Psychedelics (49)
Radiopharmaceuticals (302)
Rare diseases (988)
Real estate (5960)
Recruiting (70)
Regulatory (24957)
Reports (54)
Research institute (2404)
Resumes & cover letters (353)
Rett syndrome (32)
RNA editing (17)
RSV (85)
Schizophrenia (163)
Series A (266)
Series B (200)
Service/supplier (11)
Sickle cell disease (106)
Special edition (22)
Spinal muscular atrophy (164)
Sponsored (45)
Startups (3624)
State (2)
Stomach cancer (18)
Supply chain (117)
Tariffs (85)
The Weekly (57)
Vaccines (1054)
Venture capital (98)
Weight loss (420)
Women's health (109)
Worklife (19)
Date
Last 7 days (636)
Last 30 days (2518)
Last 365 days (29868)
2026 (7978)
2025 (30171)
2024 (35213)
2023 (40075)
2022 (51174)
2021 (55714)
2020 (54083)
2019 (46539)
2018 (35018)
2017 (32108)
2016 (31482)
2015 (37552)
2014 (31318)
2013 (26348)
2012 (28573)
2011 (29265)
2010 (27328)
Location
Africa (738)
Alabama (90)
Alaska (7)
Arizona (331)
Arkansas (13)
Asia (39454)
Australia (6451)
California (12244)
Canada (3506)
China (1224)
Colorado (522)
Connecticut (520)
Delaware (366)
Europe (85210)
Florida (1847)
Georgia (393)
Hawaii (3)
Idaho (62)
Illinois (954)
India (80)
Indiana (558)
Iowa (22)
Japan (485)
Kansas (129)
Kentucky (44)
Louisiana (38)
Maine (73)
Maryland (1481)
Massachusetts (8749)
Michigan (346)
Minnesota (674)
Mississippi (6)
Missouri (138)
Montana (33)
Nebraska (29)
Nevada (135)
New Hampshire (82)
New Jersey (3267)
New Mexico (28)
New York (3231)
North Carolina (1552)
North Dakota (8)
Northern California (6054)
Ohio (365)
Oklahoma (22)
Oregon (41)
Pennsylvania (2481)
Puerto Rico (26)
Rhode Island (50)
South America (1111)
South Carolina (76)
South Dakota (1)
Southern California (4812)
Tennessee (199)
Texas (1923)
United States (43373)
Utah (367)
Vermont (1)
Virginia (291)
Washington D.C. (80)
Washington State (980)
West Virginia (4)
Wisconsin (118)
Wyoming (2)
726,272 Results for "millenium biologix inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
KOMO Biosciences Grants Research License to Caravan Biologix for KOMbine™ Targeted Insertion Gene Editing Platform
July 24, 2025
·
3 min read
Pharm Country
Carmell Announces Successful Closing of Axolotl Biologix Sale Transaction
Carmell Corporation announced the successful closing of the previously announced sale of its wholly owned subsidiary, Axolotl Biologix to the initial sellers of AxoBio for 3,845,337 shares of Carmell common stock, 4,243 shares of Carmell preferred stock and cancellation of $8 million in notes payable.
March 27, 2024
·
5 min read
Pharm Country
Carmell Corporation Announces Completion of Post-Merger Integration with Axolotl Biologix and New Organizational Structure Aligned with Focus on Aesthetics
Carmell Corporation, a regenerative care company, announced the completion of post-merger integration with Flagstaff-based Axolotl Biologix, a profitable regenerative medicine company.
September 5, 2023
·
4 min read
Business
Caravan Biologix, Inc. Collaborates with MDimune on Cell-Derived NanoVesicles for Cancer
Caravan Biologix, Inc., a developer of novel cell-derived vesicle (CDV) therapeutics targeting specific cancers and gene therapy-related diseases, today announced that it has entered into an agreement with Seoul-based MDimune Inc. to apply their nanovesicle technology to enhance the effects of chimeric antigen receptor-expressing natural killer (CAR-NK) cells on various solid tumor cancers.
September 15, 2022
·
3 min read
Deals
Carmell Announces Successful Closing of Merger with Axolotl Biologix and Launch of a New Brand Identity
Carmell Corporation, a regenerative care company announced the successful closing of the previously announced merger with Flagstaff-based Axolotl Biologix, a profitable regenerative medicine company developing products for active soft tissue repair, aesthetics and orthopedic indications.
August 9, 2023
·
5 min read
Deals
Carmell Therapeutics Announces Merger with Axolotl Biologix, a Profitable Regenerative Medicine Company
Carmell Therapeutics Corporation (Nasdaq: CTCX) (“Carmell”), a regenerative medicine company today announced the execution of a definitive agreement and plan of merger (the “Merger Agreement”) with Flagstaff-based Axolotl Biologix, a profitable regenerative medicine company developing products for active soft tissue repair, aesthetics and orthopedic indications (“Axolotl”).
July 27, 2023
·
6 min read
Press Releases
Inscobee Inc. and Apimeds, Inc. Reaffirms Appointment of New Board of Directors for Apimeds Pharmaceuticals US, Inc.
March 25, 2026
·
3 min read
Press Releases
Apollomics Inc. Announces $2.0 Million Bridge Financing
April 1, 2026
·
4 min read
Press Releases
Forte Biosciences, Inc. Announces 2025 Results and Provides Update
April 1, 2026
·
7 min read
Press Releases
RxSight, Inc. to Participate in the 25th Annual Needham Virtual Healthcare Conference
April 3, 2026
·
1 min read
1 of 72,628
Next